Radiopharm Theranostics (ASX:RAD) Total Assets : A$63.29 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Total Assets?

Radiopharm Theranostics's Total Assets for the quarter that ended in Dec. 2023 was A$63.29 Mil.

During the past 12 months, Radiopharm Theranostics's average Total Assets Growth Rate was 0.90% per year.

Total Assets is connected with ROA %. Radiopharm Theranostics's annualized ROA % for the quarter that ended in Dec. 2023 was -71.64%. Total Assets is also linked to Revenue through Asset Turnover. Radiopharm Theranostics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Radiopharm Theranostics Total Assets Historical Data

The historical data trend for Radiopharm Theranostics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Total Assets Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Total Assets

83.38

74.95

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	91.05	83.38	85.07	74.95	63.29

Radiopharm Theranostics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Radiopharm Theranostics's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (A: Jun. 2023 )	+	Total Liabilities (A: Jun. 2023 )
	=	45.579	+	29.37
	=	74.95

Radiopharm Theranostics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	24.343	+	38.95
	=	63.29

Radiopharm Theranostics (ASX:RAD) Total Assets Explanation

Total Assets is connected with ROA %.

Radiopharm Theranostics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-49.516	/	( (74.95	+	63.293)	/ 2 )
	=	-49.516	/	69.1215
	=	-71.64 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Radiopharm Theranostics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (74.95	+	63.293)	/ 2 )
=	0	/	69.1215
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Radiopharm Theranostics Total Assets Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (ASX:RAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

RDPTF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines